OHLCX Market Research
Delayed

VRTX

Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for serious diseases, especially cystic fibrosis.

−2.66 (−0.51%) Nov 20, 2026 16:43 ET Delayed
Open
524.71
High
531.37
Low
513.80
Prev close
520.66
Volume
2M
Avg vol 10
1M

Today · Market closed · opens Mon 9:30 AM

Price

VRTX chart

Updating chart…

Scroll or pinch to zoom, drag to pan, or use the buttons on the chart. About the price history

Signals

Technical analysis

Daily bars · last bar Nov 20, 2026 · close 518.00

Strong sellNeutralStrong buy
Neutral
score −0.06 · 18 signalling
4Buy
9Neutral
5Sell

No clear lean. 4 buy, 9 neutral and 5 sell across 18 signals. Stochastic, Stoch RSI, Williams %R and CCI sit in oversold territory. Trend strength is weak (ADX 12).

How to read this →

Trend

MACD 12, 26, 9
Below signal line, still above zero
MACD 1.54 · Signal 5.18 · Hist −3.64
Sell
ADX 14
Weak trend, −DI ahead
ADX 11.59 · +DI 19.42 · −DI 25.26
Neutral
Parabolic SAR 0.02, 0.2
Above price, 39.71 over the close
557.71
Sell
Ichimoku 9, 26, 52
Price above cloud, conversion level with base
Conv 533.03 · Base 533.08 · A 503.93 · B 512.88
Neutral

Momentum

RSI 14
Mid-range, no extreme
42.15
Neutral
Stoch 14, 3
Oversold, %K still below %D
%K 8.72 · %D 12.09
Neutral
Stoch RSI 14, 14, 3, 3
Oversold, %K level with %D
%K 2.43 · %D 2.43
Neutral
Williams %R 14
Oversold zone, still rising
−91.28
Buy
CCI 14
Below −100, turning up
−208.96
Buy
MFI 14
Below midpoint, not oversold
45.00
Neutral
ROC 12
Price down 5.65% over 12 bars
−5.65%
Sell
AO 5, 35
Above zero, falling
6.75
Neutral
TRIX 18
Above zero
0.145
Buy
KST 10/15/20/30, 3
Below its signal line
KST 41.07 · Signal 49.14
Sell

Volatility

Bollinger 20, 2
Lower half, %b 0.07
Up 561.88 · Mid 538.19 · Low 514.49
Neutral
Keltner 20, 10, 1.5
Inside the channel, lower half
Up 556.23 · Mid 533.24 · Low 510.26
Neutral

Volume

VWAP 345-bar
Close 13.3% above VWAP
457.39
Buy
Force Index 1
Negative, sellers in control
−4.7M
Sell
ATR
15.34
2.96% of close
A/D Line
−20.6M
cumulative
OBV
7.2M
cumulative
Volume Profile
450.86 – 465.59
POC · bull 54.8M · bear 51.7M · 51 / 49
Risk and return

Performance

Daily returns for Jan 1, 2026 – Nov 22, 2026 (YTD). About the returns · About the risk figures

1 month return

-3.77%

Change in value over the past month.

3 month return

-5.95%

Change in value over the last three months.

Max drawdown

15.21%

Largest fall from a peak to the low that followed.

Standard deviation

29.80%

How far daily returns stray from their average, annualised.

Sharpe ratio

0.64

Return above the risk-free rate per unit of volatility.

Calmar ratio

1.25

Annualised return against the maximum drawdown.

About

VRTX summary

Loading summary…

Questions

VRTX, answered

When was Vertex founded?

Vertex was founded in 1989 and is headquartered in Boston, Massachusetts.

Is VRTX publicly traded?

Yes, Vertex is publicly traded on the NASDAQ under the ticker symbol VRTX.

What is Vertex’s commitment to innovation?

Vertex is committed to innovation, investing significantly in research to develop groundbreaking therapies for unmet medical needs.

What diseases does Vertex focus on?

Vertex primarily focuses on cystic fibrosis, but also explores therapies for other serious genetic diseases and pain.

How does Vertex support patient access to its medications?

Vertex has programs to help patients access their medications, including financial assistance and patient education resources.

How does Vertex engage with the community?

Vertex engages with the community through initiatives aimed at supporting patients, advocacy, and scientific research.

What is Vertex’s approach to clinical trials?

Vertex conducts rigorous clinical trials to ensure the safety and efficacy of its therapies before they reach the market.

How can investors find more information about Vertex?

Investors can find financial reports, news, and updates on Vertex’s official investor relations website.

What challenges does Vertex face?

Vertex faces challenges such as competition from other biotech companies, regulatory hurdles, and the high cost of drug development.

What is the financial outlook for Vertex?

Vertex has a strong financial outlook due to its successful products and ongoing R&D efforts, though market competition remains a consideration.

News

VRTX in the news

Empower Your VRTX Trading Now

Take control of your trading with OHLCX. Our platform offers unparalleled analysis and technical support for VRTX, designed to enhance your market performance. Transform your trading strategy now and experience the difference with our expert tools!

Unlock Full Potential Now

Disclaimers

The information displayed on this site is sourced from third-party providers and is believed to be reliable. OHLCX has not independently verified this data and does not guarantee its accuracy. Content is for educational and informational purposes only and is not financial or investment advice.

With any investment, your capital is at risk. Past performance is no guarantee of future results. Consult your provider's terms and privacy policies where applicable.

Prices, charts and every figure derived from them are delayed by at least 15 minutes and are provided for information only; we do not guarantee their accuracy or timeliness.

Securities products are: Not FDIC insured · Not bank guaranteed · May lose value

Trademarks and logos are the property of their respective owners and do not represent endorsements of any kind.